- 現金殖利率: 25.14%、總殖利率: 44.47%、5年平均現金配發率: 86.13%
- 要留意資產負債表的未分配盈餘和配息能力, 如果為負值, 可能會無法發放股利
- 股利有2個稅要支出, 分別是綜合所得稅和健保補充保費(單筆股利達2萬元以上, 課2.11%)
| EPS YoY | 現金股利 YoY | 股票股利 YoY | 現金配發率 YoY | 股票配發率 YoY | 全部配發率 YoY | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2023 (10) | 13.37 | 20.89 | 9.29 | -6.16 | 3.48 | 0 | 69.48 | -22.37 | 26.03 | 0 | 95.51 | 6.7 |
| 2022 (9) | 11.06 | -32.56 | 9.90 | -36.46 | 0.00 | 0 | 89.51 | -5.78 | 0.00 | 0 | 89.51 | -27.26 |
| 2021 (8) | 16.40 | 34.65 | 15.58 | 42.94 | 4.60 | 0 | 95.00 | 6.16 | 28.05 | 0 | 123.05 | 37.5 |
| 2020 (7) | 12.18 | -19.6 | 10.90 | -17.49 | 0.00 | 0 | 89.49 | 2.63 | 0.00 | 0 | 89.49 | 2.63 |
| 2019 (6) | 15.15 | 15.65 | 13.21 | 22.54 | 0.00 | 0 | 87.19 | 5.96 | 0.00 | 0 | 87.19 | 5.96 |
| 2018 (5) | 13.10 | 0 | 10.78 | 0 | 0.00 | 0 | 82.29 | 0 | 0.00 | 0 | 82.29 | 0 |
| 2017 (4) | -0.64 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 0 |
| 2016 (3) | -6.31 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 0 |
| EPS QoQ YoY | 本業EPS QoQ YoY | 累計EPS QoQ YoY | |||||||
|---|---|---|---|---|---|---|---|---|---|
| 24Q3 (20) | 1.96 | -34.88 | -41.49 | 1.73 | -5.46 | -23.79 | 4.44 | 32.93 | -51.74 |
| 24Q2 (19) | 3.01 | 812.12 | 12.31 | 1.83 | 445.28 | 1.67 | 3.34 | 912.12 | -42.91 |
| 24Q1 (18) | 0.33 | -92.12 | -89.62 | -0.53 | -114.32 | -122.36 | 0.33 | -97.54 | -89.62 |
| 23Q4 (17) | 4.19 | 25.07 | 34.73 | 3.70 | 63.0 | 43.97 | 13.39 | 45.54 | 20.74 |
| 23Q3 (16) | 3.35 | 25.0 | 39.58 | 2.27 | 26.11 | 28.25 | 9.20 | 57.26 | 15.14 |
| 23Q2 (15) | 2.68 | -15.72 | -44.86 | 1.80 | -24.05 | -13.04 | 5.85 | 83.96 | -28.4 |
| 23Q1 (14) | 3.18 | 2.25 | -3.93 | 2.37 | -7.78 | 58.0 | 3.18 | -71.33 | -3.93 |
| 22Q4 (13) | 3.11 | 29.58 | -30.89 | 2.57 | 45.2 | 11.74 | 11.09 | 38.8 | -32.87 |
| 22Q3 (12) | 2.40 | -50.62 | -45.33 | 1.77 | -14.49 | -19.55 | 7.99 | -2.2 | -33.53 |
| 22Q2 (11) | 4.86 | 46.83 | 8.0 | 2.07 | 38.0 | -11.16 | 8.17 | 146.83 | 7.08 |
| 22Q1 (10) | 3.31 | -26.44 | 5.75 | 1.50 | -34.78 | -4.46 | 3.31 | -79.96 | 5.75 |
| 21Q4 (9) | 4.50 | 2.51 | 14.21 | 2.30 | 4.55 | 16.75 | 16.52 | 37.44 | 33.98 |
| 21Q3 (8) | 4.39 | -2.44 | 74.9 | 2.20 | -5.58 | 69.23 | 12.02 | 57.54 | 43.1 |
| 21Q2 (7) | 4.50 | 43.77 | 49.5 | 2.33 | 48.41 | 55.33 | 7.63 | 143.77 | 29.54 |
| 21Q1 (6) | 3.13 | -20.56 | 8.68 | 1.57 | -20.3 | 9.79 | 3.13 | -74.61 | 8.68 |
| 20Q4 (5) | 3.94 | 56.97 | 50.38 | 1.97 | 51.54 | 51.54 | 12.33 | 46.79 | -20.19 |
| 20Q3 (4) | 2.51 | -16.61 | 0.0 | 1.30 | -13.33 | 0.0 | 8.40 | 42.61 | 0.0 |
| 20Q2 (3) | 3.01 | 4.51 | 0.0 | 1.50 | 4.9 | 0.0 | 5.89 | 104.51 | 0.0 |
| 20Q1 (2) | 2.88 | 9.92 | 0.0 | 1.43 | 10.0 | 0.0 | 2.88 | -81.36 | 0.0 |
| 19Q4 (1) | 2.62 | 0.0 | 0.0 | 1.30 | 0.0 | 0.0 | 15.45 | 0.0 | 0.0 |
| 年/月 | 營收 | 月增率(%) | 去年同期年增率(%) | 累計營收 | 累計營收年增率(%) | 近三月累計營收 | 存貨銷售比 | 自結稅前EPS | 自結稅前累計EPS | 備註(年增率變動50%需說明原因) |
|---|---|---|---|---|---|---|---|---|---|---|
| 2024/11 | 3.58 | 87.96 | 25.66 | 20.18 | 6.44 | 7.29 | N/A | - | ||
| 2024/10 | 1.91 | 5.82 | 0.53 | 16.6 | 3.04 | 5.48 | N/A | - | ||
| 2024/9 | 1.8 | 1.57 | 8.33 | 14.69 | 3.37 | 5.17 | 0.6 | - | ||
| 2024/8 | 1.77 | 10.99 | 0.58 | 12.89 | 2.72 | 4.98 | 0.63 | - | ||
| 2024/7 | 1.6 | -0.61 | 4.35 | 11.12 | 3.07 | 4.86 | 0.64 | - | ||
| 2024/6 | 1.61 | -2.69 | 2.21 | 9.52 | 2.86 | 5.0 | 0.56 | - | ||
| 2024/5 | 1.65 | -5.02 | -1.71 | 7.91 | 2.99 | 5.07 | 0.56 | - | ||
| 2024/4 | 1.74 | 50.51 | 15.71 | 6.26 | 4.31 | 5.04 | 0.56 | - | ||
| 2024/3 | 1.68 | 3.57 | 5.56 | 5.04 | 12.08 | 5.04 | 0.48 | - | ||
| 2024/2 | 1.62 | -7.04 | 11.14 | 3.36 | 15.64 | 5.14 | 0.47 | - | ||
| 2024/1 | 1.74 | -2.26 | 20.17 | 1.74 | 20.17 | 6.38 | 0.38 | - | ||
| 2023/12 | 1.78 | -37.53 | 16.7 | 20.74 | 13.04 | 6.53 | 0.4 | - | ||
| 2023/11 | 2.85 | 50.37 | 31.6 | 18.96 | 12.71 | 6.41 | 0.41 | - | ||
| 2023/10 | 1.9 | 14.03 | 29.57 | 16.11 | 9.91 | 5.32 | 0.5 | - | ||
| 2023/9 | 1.66 | -5.68 | 20.59 | 14.21 | 7.73 | 4.96 | 0.56 | - | ||
| 2023/8 | 1.76 | 15.15 | 23.32 | 12.55 | 6.23 | 4.87 | 0.57 | - | ||
| 2023/7 | 1.53 | -2.65 | 5.47 | 10.79 | 3.88 | 4.79 | 0.58 | - | ||
| 2023/6 | 1.57 | -6.43 | -0.9 | 9.25 | 3.62 | 4.76 | 0.45 | - | ||
| 2023/5 | 1.68 | 11.82 | 4.92 | 7.68 | 4.6 | 4.77 | 0.45 | - | ||
| 2023/4 | 1.5 | -5.32 | 6.14 | 6.0 | 4.51 | 4.55 | 0.47 | - | ||
| 2023/3 | 1.59 | 9.05 | 11.21 | 4.49 | 3.97 | 4.49 | 0.45 | - | ||
| 2023/2 | 1.46 | 0.51 | 6.55 | 2.91 | 0.4 | 4.43 | 0.45 | - | ||
| 2023/1 | 1.45 | -5.09 | -5.1 | 1.45 | -5.1 | 5.14 | 0.39 | - | ||
| 2022/12 | 1.53 | -29.55 | -7.3 | 18.35 | 11.42 | 5.16 | 0.3 | - | ||
| 2022/11 | 2.17 | 48.06 | 22.33 | 16.82 | 13.5 | 5.01 | 0.31 | - | ||
| 2022/10 | 1.46 | 6.12 | 0.2 | 14.66 | 12.3 | 4.27 | 0.36 | - | ||
| 2022/9 | 1.38 | -3.54 | -0.02 | 13.19 | 13.82 | 4.26 | 0.38 | - | ||
| 2022/8 | 1.43 | -1.51 | 0.89 | 11.81 | 15.69 | 4.47 | 0.37 | - | ||
| 2022/7 | 1.45 | -8.53 | 3.96 | 10.38 | 18.08 | 4.64 | 0.35 | - | ||
| 2022/6 | 1.59 | -0.94 | 10.96 | 8.93 | 20.75 | 4.61 | 0.27 | - | ||
| 2022/5 | 1.6 | 13.12 | 16.11 | 7.34 | 23.1 | 4.45 | 0.28 | - | ||
| 2022/4 | 1.42 | -0.8 | 21.58 | 5.74 | 25.2 | 4.21 | 0.3 | - | ||
| 2022/3 | 1.43 | 4.47 | 20.18 | 4.32 | 26.43 | 4.32 | 0.22 | - | ||
| 2022/2 | 1.37 | -10.48 | 24.09 | 2.89 | 29.77 | 4.54 | 0.2 | - | ||
| 2022/1 | 1.53 | -7.28 | 35.31 | 1.53 | 35.31 | 4.95 | 0.19 | - | ||
| 2021/12 | 1.65 | -7.03 | 35.69 | 16.47 | 60.06 | 4.88 | 0.1 | 因直播成長與大研生醫熱銷，惟大研採用國際頂級臨床醫學實證原料與研發專利配方成本頗高，尚有累計虧損，長期來看需謹慎觀察 | ||
| 2021/11 | 1.77 | 21.27 | 53.37 | 14.82 | 63.32 | 4.61 | 0.1 | 因直播成長與大研生醫熱銷，惟大研採用國際頂級臨床醫學實證原料與研發專利配方成本頗高，尚有累計虧損，長期來看需謹慎觀察 | ||
| 2021/10 | 1.46 | 5.88 | 87.53 | 13.05 | 64.77 | 4.26 | 0.11 | 因直播成長與大研生醫熱銷，惟大研採用國際頂級臨床醫學實證原料與研發專利配方成本頗高，尚有大額累計虧損，長期來看需謹慎觀察 | ||
| 2021/9 | 1.38 | -2.65 | 67.03 | 11.59 | 62.29 | 4.19 | 0.1 | 因直播成長與大研生醫熱銷，惟大研採用國際頂級臨床醫學實證原料與研發專利配方成本頗高，尚有大額累計虧損，長期來看需謹慎觀察 | ||
| 2021/8 | 1.42 | 1.48 | 81.09 | 10.21 | 61.67 | 4.25 | 0.1 | 因直播成長與大研生醫熱銷，惟大研採用國際頂級臨床醫學實證原料與研發專利配方成本頗高，尚有大額累計虧損，長期來看需謹慎觀察 | ||
| 2021/7 | 1.4 | -2.38 | 74.18 | 8.79 | 58.92 | 4.21 | 0.1 | 因直播成長與大研生醫熱銷，惟大研採用國際頂級臨床醫學實證原料與研發專利配方成本頗高，尚有大額累計虧損，長期來看需謹慎觀察 | ||
| 2021/6 | 1.43 | 3.65 | 72.55 | 7.4 | 56.34 | 3.98 | 0.1 | 因直播成長與大研生醫熱銷，惟大研採用國際頂級臨床醫學實證原料與研發專利配方成本頗高，尚有大額累計虧損，長期來看需謹慎觀察 | ||
| 2021/5 | 1.38 | 18.46 | 68.72 | 5.96 | 52.89 | 3.73 | 0.11 | 因直播成長與大研生醫熱銷，惟大研採用國際頂級臨床醫學實證原料與研發專利配方成本頗高，尚有大額累計虧損，長期來看需謹慎觀察 | ||
| 2021/4 | 1.17 | -1.94 | 55.77 | 4.58 | 48.69 | 3.46 | 0.12 | 因直播成長與大研生醫熱銷，惟大研採用國際頂級臨床醫學實證原料與研發專利配方成本頗高，尚有大額累計虧損，長期來看需謹慎觀察 | ||
| 2021/3 | 1.19 | 7.87 | 53.06 | 3.42 | 46.42 | 3.42 | 0.07 | 因直播成長與大研生醫熱銷，惟大研採用國際頂級臨床醫學實證原料與研發專利配方成本頗高，尚在虧損中，長期來看需謹慎觀察。 | ||
| 2021/2 | 1.1 | -2.38 | 40.2 | 2.23 | 43.11 | 3.44 | 0.07 | - | ||
| 2021/1 | 1.13 | -7.02 | 46.07 | 1.13 | 46.07 | 3.5 | 0.07 | - | ||
| 2020/12 | 1.21 | 5.07 | 35.46 | 10.29 | -0.77 | 3.15 | 0.03 | - | ||
| 2020/11 | 1.16 | 48.28 | 58.69 | 9.08 | -4.2 | 2.76 | 0.04 | 因1111單身節與購物節檔期，使直播、交友與保健品收入都有所增加，有可能為短期效應，長期來看還需謹慎觀察。 | ||
| 2020/10 | 0.78 | -5.68 | -3.52 | 7.92 | -9.43 | 2.39 | 0.04 | - | ||
| 2020/9 | 0.83 | 5.53 | -3.61 | 7.14 | -10.04 | 2.41 | 0.01 | - | ||
| 2020/8 | 0.78 | -2.39 | -12.98 | 6.31 | -10.81 | 2.41 | 0.01 | - | ||
| 2020/7 | 0.8 | -3.29 | -8.77 | 5.53 | -10.5 | 2.45 | 0.01 | - | ||
| 2020/6 | 0.83 | 1.35 | -13.54 | 4.73 | -10.78 | 2.4 | 0.02 | - | ||
| 2020/5 | 0.82 | 9.36 | -11.1 | 3.9 | -10.18 | 2.34 | 0.02 | - | ||
| 2020/4 | 0.75 | -3.64 | -18.62 | 3.08 | -9.93 | 2.31 | 0.02 | - | ||
| 2020/3 | 0.78 | -1.18 | -16.47 | 2.33 | -6.74 | 2.33 | 0.04 | - | ||
| 2020/2 | 0.79 | 1.69 | -1.5 | 1.56 | -0.99 | 2.45 | 0.04 | - | ||
| 2020/1 | 0.77 | -13.77 | -0.46 | 0.77 | -0.46 | 0.0 | N/A | - | ||
| 2019/12 | 0.9 | 23.09 | -10.39 | 10.37 | 24.94 | 0.0 | N/A | - |
